FDA Accepts sNDA for Brukinsa in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
The approval was based on data from the open-label, multi-cohort phase 2 UNITY-NHL Trial.
Investigators tested the utility of ultra-deep genomic testing to predict relapse in patients with myelodysplastic syndrome initiating conditioning therapy for allogeneic hematopoietic cell transplant (alloHCT).
A year-end update on WM, a distinct entity of lymphoplasmacytic lymphoma presenting with monoclonal pleomorphic immunoglobulin M (IgM) proteins, was recently published in the American Journal of Hematology.
Observational, retrospective study revealed factors that may be linked to higher mortality risk in patients with MPN and COVID-19.
As follicular lymphoma (FL) survival rates have improved, concern that patients are at increased risk for the development of a secondary primary malignancy (SPM) has arisen.
Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
A cost analysis shows daratumumab may be better used as a second-line treatment for transplant-ineligible patients with multiple myeloma.
Investigators compared elotuzumab plus lenalidomide, bortezomib, and dexamethasone (RVd) with RVd alone in the induction and maintenance therapy settings.